ARYx Therapeutics, Inc.
ARYX · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Market Cap | $88,076 | $54,996 | $72,895 | $8,246 |
| - Cash | $7,409 | $35,999 | $55,476 | $18,660 |
| + Debt | $11,695 | $14,682 | $6,980 | $9,876 |
| Enterprise Value | $92,362 | $33,679 | $24,399 | -$538 |
| Revenue | $0 | $19,724 | $4,158 | $4,739 |
| % Growth | -100% | 374.4% | -12.3% | – |
| Gross Profit | $0 | $19,492 | $3,896 | $2,623 |
| % Margin | – | 98.8% | 93.7% | 55.3% |
| EBITDA | -$30,060 | -$29,320 | -$27,562 | -$27,368 |
| % Margin | – | -148.7% | -662.9% | -577.5% |
| Net Income | -$33,167 | -$31,218 | -$27,561 | -$27,328 |
| % Margin | – | -158.3% | -662.8% | -576.7% |
| EPS Diluted | -1.21 | -1.65 | -2.93 | -26.84 |
| % Growth | 26.7% | 43.7% | 89.1% | – |
| Operating Cash Flow | -$34,967 | -$45,218 | -$27,705 | -$4,213 |
| Capital Expenditures | -$141 | -$644 | -$499 | -$962 |
| Free Cash Flow | -$35,108 | -$45,862 | -$28,204 | -$5,175 |